Analysis of the Reasons for Non-Uptake of Predictive Testing for Huntington's Disease in Spain: A Qualitative Study

Overview

Journal J Genet Couns

Publisher Wiley

Specialty Genetics

Date 2015 Apr 30

PMID 25921556

Citations 3

Authors

Jesus Rivera-Navarro

Esther Cubo

Natividad Mariscal

Affiliations

Soon will be listed here.

Abstract

Children of persons affected by Huntington's disease (HD) have a 50% chance of inheriting the disease. Genetic testing in Spain is offered to individuals (presymptomatic test) or mothers of fetuses (prenatal) who run the risk of suffering from HD. The objective of this study is to analyze the factors that influence the decisions of adult children of persons affected with HD regarding predictive testing. A qualitative research methodology was used involving 4 focus groups (FGs) made up of adult children of persons with HD in different cities in Spain. The results of the study showed that over half of the focus group participants were inclined to decline genetic testing. The main explanatory determinants for taking or not taking the predictive test are: Maturity of the individual at risk, which was directly related to age; Ability to cope with a positive test result; Experience of living with HD sufferers; Information about testing and psychological support; Attitude of the family; Social visibility of genetic testing; Personality and temperament of each subject at risk of HD. These results imply that these factors should be analyzed in more detail in quantitative studies in order to help the Spanish Department of Health understand why some children of parents with HD decline genetic testing, so that they may and apply these data when creating specific policy regarding this issue.

Citing Articles

Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.

Howard J, Chaouch A, Douglas A, MacLeod R, Roggenbuck J, McNeill A Eur J Hum Genet. 2024; 33(1):7-13.

PMID: 39501102 PMC: 11711763. DOI: 10.1038/s41431-024-01718-4.

Experiences of predictive genetic testing in inherited motor neuron disease: Findings from a qualitative interview study.

Howard J, Forrest Keenan K, Mazanderani F, Turner M, Locock L J Genet Couns. 2024; 34(1):e1904.

PMID: 38628040 PMC: 11735176. DOI: 10.1002/jgc4.1904.

"This could be me": exploring the impact of genetic risk for Huntington's disease young caregivers.

Dondanville D, Hanson-Kahn A, Kavanaugh M, Siskind C, Fanos J J Community Genet. 2018; 10(2):291-302.

PMID: 30430455 PMC: 6435781. DOI: 10.1007/s12687-018-0395-z.

Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD.

Downing N, Lourens S, De Soriano I, Long J, Paulsen J J Huntingtons Dis. 2016; 5(4):357-368.

PMID: 27983559 PMC: 6258187. DOI: 10.3233/JHD-160185.

References

Williams J, Erwin C, Juhl A, Mengeling M, Bombard Y, Hayden M . In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B(6):1150-9. PMC: 3035936. DOI: 10.1002/ajmg.b.31080. View

Chisholm L, Flavin K, Paulsen J, Ready R . Psychological well-being in persons affected by Huntington's disease: a comparison of at-risk, prodromal, and symptomatic groups. J Health Psychol. 2012; 18(3):408-18. DOI: 10.1177/1359105312444646. View

Loi S, Chiu E . Witchcraft and Huntington's disease: a salutary history of societal and medical stigmatisation. Australas Psychiatry. 2012; 20(5):438-41. DOI: 10.1177/1039856212459587. View

Walker F . Huntington's Disease. Semin Neurol. 2007; 27(2):143-50. DOI: 10.1055/s-2007-971176. View

Hoppitt T, Pall H, Calvert M, Gill P, Yao G, Ramsay J . A systematic review of the incidence and prevalence of long-term neurological conditions in the UK. Neuroepidemiology. 2010; 36(1):19-28. PMC: 2997442. DOI: 10.1159/000321712. View

Bombard Y, Veenstra G, Friedman J, Creighton S, Currie L, Paulsen J . Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ. 2009; 338:b2175. PMC: 2694258. DOI: 10.1136/bmj.b2175. View

Huggins M, Bloch M, Wiggins S, Adam S, Suchowersky O, Trew M . Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992; 42(4):508-15. DOI: 10.1002/ajmg.1320420417. View

Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N . The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012; 27(9):1083-91. DOI: 10.1002/mds.25075. View

Williams J, Erwin C, Juhl A, Mills J, Brossman B, Paulsen J . Personal factors associated with reported benefits of Huntington disease family history or genetic testing. Genet Test Mol Biomarkers. 2010; 14(5):629-36. PMC: 2957234. DOI: 10.1089/gtmb.2010.0065. View

10.

Paneque M, Sequeiros J, Skirton H . Quality assessment of genetic counseling process in the context of presymptomatic testing for late-onset disorders: a thematic analysis of three review articles. Genet Test Mol Biomarkers. 2011; 16(1):36-45. DOI: 10.1089/gtmb.2011.0023. View

11.

Wahlin T, Lundin A, Backman L, Almqvist E, Haegermark A, Winblad B . Reactions to predictive testing in Huntington disease: case reports of coping with a new genetic status. Am J Med Genet. 1998; 73(3):356-65. DOI: 10.1002/(sici)1096-8628(19971219)73:3<356::aid-ajmg24>3.0.co;2-h. View

12.

Erwin C, Williams J, Juhl A, Mengeling M, Mills J, Bombard Y . Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B(5):1081-93. PMC: 3593716. DOI: 10.1002/ajmg.b.31079. View

13.

Coulson N, Buchanan H, Aubeeluck A . Social support in cyberspace: a content analysis of communication within a Huntington's disease online support group. Patient Educ Couns. 2007; 68(2):173-8. DOI: 10.1016/j.pec.2007.06.002. View

14.

Harper P . The epidemiology of Huntington's disease. Hum Genet. 1992; 89(4):365-76. DOI: 10.1007/BF00194305. View

15.

Rivera-Navarro J, Cubo E, Almazan J . The diagnosis of Tourette's Syndrome: communication and impact. Clin Child Psychol Psychiatry. 2008; 14(1):13-23. DOI: 10.1177/1359104508100127. View

16.

Morrison P . Accurate prevalence and uptake of testing for Huntington's disease. Lancet Neurol. 2010; 9(12):1147. DOI: 10.1016/S1474-4422(10)70287-8. View

17.

Kessler S, Field T, Worth L, Mosbarger H . Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet. 1987; 26(2):259-70. DOI: 10.1002/ajmg.1320260204. View

18.

Sizer E, Haw T, Wessels T, Kromberg J, Krause A . The utilization and outcome of diagnostic, predictive, and prenatal genetic testing for huntington disease in johannesburg, South Africa. Genet Test Mol Biomarkers. 2011; 16(1):58-62. DOI: 10.1089/gtmb.2011.0007. View

19.

Timman R, Roos R, Maat-Kievit A, Tibben A . Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol. 2004; 23(2):189-97. DOI: 10.1037/0278-6133.23.2.189. View

20.

Bernhardt C, Schwan A, Kraus P, Epplen J, Kunstmann E . Decreasing uptake of predictive testing for Huntington's disease in a German centre: 12 years' experience (1993-2004). Eur J Hum Genet. 2008; 17(3):295-300. PMC: 2986171. DOI: 10.1038/ejhg.2008.164. View